Financial Contrast: Cardiff Oncology (NASDAQ:CRDF) versus Invizyne Technologies (NASDAQ:IZTC)

Cardiff Oncology (NASDAQ:CRDF) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Cardiff Oncology and Invizyne Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-6,238.17%	-73.97%	-60.40%
Invizyne Technologies	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cardiff Oncology and Invizyne Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	0	0	3	0	3.00
Invizyne Technologies	0	0	0	0	0.00

Cardiff Oncology presently has a consensus target price of $12.00, suggesting a potential upside of 351.13%. Given Cardiff Oncology’s stronger consensus rating and higher possible upside, research analysts clearly believe Cardiff Oncology is more favorable than Invizyne Technologies.

Institutional and Insider Ownership

16.3% of Cardiff Oncology shares are owned by institutional investors. 7.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Cardiff Oncology and Invizyne Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$683,000.00	259.09	-$41.44 million	($0.94)	-2.83
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Invizyne Technologies has lower revenue, but higher earnings than Cardiff Oncology.

Summary

Cardiff Oncology beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.